AbCellera Biologics Inc. (NASDAQ:ABCL) Stock Rated “Moderate Buy” by Sell-Side Analysts

Posted by Brian Himes on Oct 8th, 2026

AbCellera Biologics Inc. (NASDAQ:ABCL – Get Free Report) has been assigned an average rating of “Moderate Buy” from the nine ratings firms that are covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell rating, two have issued a hold rating, five have given a buy rating and one has assigned a strong buy rating to the company. The average 12-month price objective among analysts that have covered the stock in the last year is $13.38.

Several research analysts recently issued reports on ABCL shares. Cantor Fitzgerald increased their price objective on AbCellera Biologics from $11.00 to $12.00 and gave the stock an “overweight” rating in a research note on Thursday, August 6th. Truist Financial raised their target price on shares of AbCellera Biologics from $12.00 to $30.00 and gave the company a “buy” rating in a research report on Tuesday, August 11th. Wall Street Zen lowered shares of AbCellera Biologics from a “hold” rating to a “sell” rating in a report on Saturday, September 26th. Weiss Ratings reiterated a “sell (d-)” rating on shares of AbCellera Biologics in a research note on Friday, July 17th. Finally, The Goldman Sachs Group started coverage on shares of AbCellera Biologics in a report on Thursday, September 24th. They set a “neutral” rating and a $13.00 price objective on the stock.

Read Our Latest Research Report on AbCellera Biologics

Institutional Investors Weigh In On AbCellera Biologics

A number of institutional investors have recently added to or reduced their stakes in ABCL. Janney Montgomery Scott LLC purchased a new stake in shares of AbCellera Biologics during the first quarter valued at about $46,000. Ground Swell Capital LLC purchased a new position in shares of AbCellera Biologics in the 1st quarter worth approximately $55,000. SG Americas Securities LLC bought a new position in shares of AbCellera Biologics during the 1st quarter worth approximately $70,000. AssuredPartners Investment Advisors LLC purchased a new stake in AbCellera Biologics during the second quarter valued at approximately $80,000. Finally, Allworth Financial LP purchased a new stake in AbCellera Biologics during the second quarter valued at approximately $91,000. Institutional investors own 61.42% of the company’s stock.

AbCellera Biologics Trading Down 2.4%

Shares of ABCL opened at $12.83 on Thursday. The firm has a fifty day moving average price of $11.13 and a 200-day moving average price of $7.25. The firm has a market capitalization of $3.93 billion, a P/E ratio of -23.76 and a beta of 1.41. AbCellera Biologics has a 12-month low of $2.74 and a 12-month high of $15.02.

AbCellera Biologics (NASDAQ:ABCL – Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.18) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.16) by ($0.02). The company had revenue of $4.05 million for the quarter, compared to the consensus estimate of $7.85 million. AbCellera Biologics had a negative net margin of 248.83% and a negative return on equity of 17.49%. Analysts predict that AbCellera Biologics will post -0.69 earnings per share for the current year.

About AbCellera Biologics

(Get Free Report)

AbCellera Biologics Inc is a biotechnology company that develops technologies for the discovery and development of antibody medicines. Its platform combines high-throughput screening, single-cell analysis, microfluidics, data science and machine learning to identify antibodies with potential therapeutic applications.

The company works with pharmaceutical and biotechnology partners worldwide, helping them discover and advance antibody candidates for areas such as cancer, infectious diseases, autoimmune disorders and other medical conditions.